Opinion

Video

HIMALAYA Study in Advanced Stage HCC

A comprehensive discussion of the HIMALAYA study, evaluating the STRIDE regimen of durvalumab plus tremelimumab in first-line treatment for advanced HCC.

Related Videos
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center
Richard Kim, MD, Moffitt Cancer Center
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Related Content
OncLive’s November Roundup of Key FDA Approvals in Oncology
December 3rd 2024

OncLive’s November Roundup of Key FDA Approvals in Oncology

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

OncLive's Top Stories of the Week
November 30th 2024

The OncFive: Top Oncology Articles for the Week of 11/24

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Suneel Kamath, MD, of Cleveland Clinic
November 27th 2024

Pancreatic Cancer Awareness Month Brings Attention to Growing Incidence and Treatment Advances

Alan P. Venook, MD, of UCSF
November 27th 2024

Targeted Therapies Represent Core 2024 NCCN GI Cancer Guideline Advancements